Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Other Disease Areas
Filter     Order     Display # 
Date Item Title
01 Feb 2008 Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
01 Feb 2008 Eisai Decides Additional Study for Pariet(R) for New Indication of Non-Erosive Gastro-Esophageal Reflux Disease in Japan
30 Jan 2008 Auris Medical completing enrolment in phase I/II clinical trial with AM-101
29 Jan 2008 Neose Announces Discontinuation of NE-180 Program
29 Jan 2008 Mentor Announces Completion of Subject Enrollment into Phase IIIb Pivotal Trial for Botulinum Toxin Type A
28 Jan 2008 NPS Pharmaceuticals Provides Update on GATTEX(TM) Clinical Development in Short Bowel Syndrome
28 Jan 2008 N30 Pharma Announces Successful Initiation of Human Studies With N30-201
28 Jan 2008 Orthologic Announces FDA Acceptance of AZX100 IND Application in Dermal/Hypertrophic Scarring; Phase 1 Human Clinical Trial to Begin 1Q2008
22 Jan 2008 ImaRx and Microbix sign Letter of Intent to manufacture and further develop the FDA-approved clot-dissolving drug, Abbokinase(R)
22 Jan 2008 FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis
18 Jan 2008 GSK Does Not Option XL784 for Further Development
17 Jan 2008 Clinical Trial to Treat Rare Skin Disorder With siRNA Technology
17 Jan 2008 FDA Approves ZymoGenetics' RECOTHROM(TM) Thrombin, topical
17 Jan 2008 CollaGenex Pharmaceuticals Announces Results of Phase 4 Clinical Study Showing Oracea Equally Effective as 100 mg Doxycycline in Treatment of Rosacea
15 Jan 2008 Kamada Announces Successful Completion of Phase I Studies with Aerosolized AAT for the Treatment of Lung Diseases
08 Jan 2008 Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
08 Jan 2008 FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
07 Jan 2008 Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
07 Jan 2008 BioSante Pharmaceuticals Announces Initiation of LibiGel(R) (Transdermal Testosterone Gel) Phase III Safety Study
07 Jan 2008 Santarus Announces Positive Clinical Results with ZEGERID Capsules in Controlling Gastric Acidity over 24 Hours
07 Jan 2008 Alizyme announces completion of recruitment into its COLAL-PRED(R) Phase III clinical trial and provides an update on its other product development and corporate activities
04 Jan 2008 TAP Pharmaceutical Products Inc. Filed New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
03 Jan 2008 Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
03 Jan 2008 Protox announces positive final results from BPH study
03 Jan 2008 Quatrx Pharmaceuticals announces positive Phase 3 results for study of ophena ™ (ospemifene) to treat postmenopausal vaginal syndrome
03 Jan 2008 NicOx announces Pfizer initiates phase 2 clinical
02 Jan 2008 Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
20 Dec 2007 ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
17 Dec 2007 Dynogen Announces Positive Results in Phase 2 IBS-d Study
17 Dec 2007 Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren's Contracture
17 Dec 2007 MGI PHARMA Announces Aquavan NDA Accepted for Review by U.S. FDA
14 Dec 2007 Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation
12 Dec 2007 AstraZeneca Files Patent Infringement Actions in Response to Crestor(TM) ANDAs
12 Dec 2007 Theravance Announces Initiation of Phase 1 Clinical Study With Investigational Medicine For Respiratory Disease
12 Dec 2007 Positive results of phase IIa AK trial
11 Dec 2007 Medicis and Revance Announce Strategic Collaboration
10 Dec 2007 Astion Pharma to Commence International Phase III Clinical Studies With ASF-1057 in Seborrheic Dermatitis
07 Dec 2007 Submission of Marketing Authorisation Application for Dapoxetine in Europe
06 Dec 2007 Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA
04 Dec 2007 HRA Pharma enters licensing agreement with PregLem to develop and commercialise ulipristal for gynecological disorders
04 Dec 2007 ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
03 Dec 2007 Bayer Schering Pharma paves the way to the next important oral contraceptive milestone
03 Dec 2007 Santarus Licenses Rights to GlaxoSmithKline for ZEGERID Immediate-Release Omeprazole Products in over 100 Countries
03 Dec 2007 Repros' Lead Product Proellex to Enter Phase 3 for the Treatment of Uterine Fibroid Indications
03 Dec 2007 Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102
03 Dec 2007 BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
30 Nov 2007 Alcon Receives FDA Approval of TRIESENCE(TM) Injectable Triamcinolone Suspension for Use in Eye Surgery
29 Nov 2007 Bionovo Describes a New Class of Therapeutic Compounds
27 Nov 2007 Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair
27 Nov 2007 Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 301 - 350 of 985

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics